CME Information
Provider Statement: This continuing medical education activity is provided by 
Support Statement: This activity is supported by an educational grant from Receptos, Inc.
Target Audience: The intended audience for this activity is neurologists and other health care professionals involved in the treatment of patients with MS.
Learning Objectives:
Upon successful completion of this educational activity, participants should be better able to:
- Evaluate the benefits and limitations of available agents for the treatment of relapsing-remitting MS (RRMS).
- Review the clinical efficacy and safety of emerging therapies for the management of RRMS.
Faculty:
Mark S. Freedman, MSc, MD, FANA, FAAN, FRCPC
Professor of Neurology
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, ON, Canada
Reviewer:
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 1/29/2018)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Faculty Member reports the following relationship(s) which are accurate at the time of original content release (2/21/2017):
Mark S. Freedman, MSc, MD, FANA, FAAN, FRCPC
Consulting Fee: Actelion, Bayer, Biogen Idec, Chugai, EMD Canada, Genzyme, Merck Serono, Novartis, Hoffman La-Roche, Sanofi-Aventis, Teva Canada Innovation
Speakers Bureau: Genzyme
Contracted Research: Genzyme
Advisory Board: Actelion, Bayer, Biogen Idec, Hoffman La-Roche, Merck Serono, MedDay, Novartis, Sanofi-Aventis
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was originally approved for 1 year from the date of original release, February 21, 2017 to February 20, 2018. It has since been recertified for an additional year and will now expire on January 29, 2019.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com